Browse Clinical Trials: Cell-Based Therapies for COVID-19
| NCT04798066 | Intermediate Size Expanded Access Protocol Evaluating HB-adMSC's for the Treatment of Post-COVID-19 Syndrome | Available | Biological: Autologous HB-adMSC's | Hope Biosciences Stem Cell Research Foundation|Hope Biosciences | 0 | USA | |
| NCT04293692 | Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus | Withdrawn | UC-MSCs|Placebo | Puren Hospital Affiliated to Wuhan University of Science and Technology|Wuhan Hamilton Bio-technology Co., Ltd | Not Applicable | 0 | China |
| NCT04341610 | ASC Therapy for Patients With Severe Respiratory COVID-19 | Withdrawn | Stem Cell Product | Rigshospitalet, Denmark | Phase 1|Phase 2 | 0 | Denmark |
| NCT04805086 | The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19 | Recruiting | Biological: MON002 | Guy's and St Thomas' NHS Foundation Trust|King's College London | Phase 1|Phase 2 | 5 | UK |
| NCT04513470 | Allocetra-OTS in COVID-19 | Recruiting | Allocetra-OTS | Hadassah Medical Organization | Phase 1 | 5 | Israel |
| NCT04313322 | Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells | Recruiting | WJ-MSCs | Stem Cells Arabia | Phase 1 | 5 | Jordan |
| NCT04522986 | An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection | Not yet recruiting | Mesenchymal stem cell | Rohto Pharmaceutical Co., Ltd. | Phase 1 | 6 | Japan |
| NCT04400032 | Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome - Vanguard | Not yet recruiting | Mesenchymal Stromal Cells | Ottawa Hospital Research Institute|Stem Cell Network | Phase 1 | 9 | Canada |
| NCT04331613 | Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS | Recruiting | CAStem | Chinese Academy of Sciences|Beijing YouAn Hospital | Phase 1|Phase 2 | 9 | China |
| NCT04452097 | Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS | Not yet recruiting | Human umbilical cord mesenchymal stem cells + best supportive care | Baylx Inc. | Phase 1 | 9 | Colombia |
| NCT04535856 | Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients | Not yet recruiting | Allogeneic mesenchymal stem cell|Placebo | Ina-Respond|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia|Daewoong Pharmaceutical Co. LTD. | Phase 1 | 9 | Indonesia |
| NCT04456361 | Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19 | Active, not recruiting | Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords | Instituto de Medicina Regenerativa | Early Phase 1 | 9 | Mexico |
| NCT04447833 | Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome | Recruiting | Mesenchymal Stromal Stem Cells - KI-MSC-PL-205 | Uppsala University|Uppsala University Hospital | Phase 1 | 9 | Sweden |
| NCT04467047 | Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19 | Not yet recruiting | Mesenchymal Stromal Cells infusion | Hospital de Clinicas de Porto Alegre | Phase 1 | 10 | Brazil |
| NCT04344548 | Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia | Not yet recruiting | Allogeneic NK transfer | Universidad Nacional de Colombia|Fundación Salud de los Andes | Phase 1|Phase 2 | 10 | Colombia |
| NCT04416139 | Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19 | Recruiting | Infusion IV of Mesenchymal Stem cells | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Phase 2 | 10 | Mexico |
| NCT04527224 | Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia | Not yet recruiting | AstroStem-V | Nature Cell Co. Ltd. | Phase 1|Phase 2 | 10 | South Korea |
| NCT04397471 | A Study to Collect Bone Marrow for Process Development and Production of BM-MSC to Treat Severe COVID19 Pneumonitis | Not yet recruiting | Bone Marrow Harvest | CCTU- Cancer Theme|Cambridge Cellular Therapies Laboratory|The Evelyn Trust|Cambridge University Hospitals NHS Foundation Trust | 10 | United Kingdom | |
| NCT04319731 | A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure | Recruiting | Human Amniotic Fluid | University of Utah | Early Phase 1 | 10 | USA |
| NCT04646603 | MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients | Not yet recruiting | MRG-001|Drug: Placebo | MedRegen LLC|Kendall Healthcare Group, Ltd. | Phase 1|Phase 2 | 12 | USA |
| NCT04742595 | SARS-CoV-2 Specific Cytotoxic T Lymphocytes for the Treatment of COVID-19 in Patients With Cancer | Recruiting | Biological: SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes | M.D. Anderson Cancer Center | Early Phase 1 | 16 | USA |
| NCT04269525 | Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia | Recruiting | UC-MSCs | ZhiYong Peng|Tuohua Biological Technology Co. Ltd|Zhongnan Hospital | Phase 2 | 16 | China |
| NCT04457726 | Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19 | Recruiting | SARS-CoV-2 Specific T Cells | KK Women's and Children's Hospital|Duke-NUS Graduate Medical School|National University Hospital, Singapore|Singapore General Hospital|Sengkang General Hospital|Changi General Hospital | Phase 1|Phase 2 | 18 | Singapore |
| NCT04737161 | Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome | Not yet recruiting | Biological: T regulatory cells | Stanford University | Phase 1 | 20 | USA |
| NCT04445454 | Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection | Recruiting | Mesenchymal stromal cells | University of Liege | Phase 1|Phase 2 | 20 | Belgium |
| NCT04525378 | MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome | Recruiting | Mesenchymal stromal cell-based therapy | D'Or Institute for Research and Education | Phase 1 | 20 | Brazil |
| NCT04451291 | Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure | Not yet recruiting | Decidual Stromal Cells (DSC) | University Health Network, Toronto|Oslo University Hospital | Not Applicable | 20 | Canada |
| NCT04252118 | Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19 | Recruiting | MSCs | Beijing 302 Hospital|Innovative Precision Medicine Group (IPM), Hangzhou, China.|Huoshenshan Hospital|Tianjin Haihe Hospital|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China|Shenzhen Third People's Hospital|Fifth Affiliated Hospital, Sun Yat-Sen University | Phase 1 | 20 | China |
| NCT04336254 | Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients | Recruiting | Allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Intravenous saline injection (Placebo) | Renmin Hospital of Wuhan University|Beijing SH Bio-Tech Corporation, Beijing (CN)|Utooth Biological Technology Co., Ltd. Hubei (CN) | Phase 1|Phase 2 | 20 | China |
| NCT04346368 | Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19) | Not yet recruiting | BM-MSCs|Placebo | Guangzhou Institute of Respiratory Disease|Guangzhou Eighth People's Hospital|Tongji Hospital, Huazhong University of Science & Technology|Guangzhou Cellgenes Biotechnology Co.,Ltd | Phase 1|Phase 2 | 20 | China |
| NCT04611256 | Mesenchymal Stem Cells in Patients Diagnosed With COVID-19 | Recruiting | MSC|Drug: Control | Hospital Reg. Lic. Adolfo Lopez Mateos|Instituto de Terapia Celular: ITC | Phase 1 | 20 | Mexico |
| NCT04444271 | Mesenchymal Stem Cell Infusion for COVID-19 Infection | Recruiting | Mesenchymal stem cells|Placebo | Dr. Zaineb Akram|National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | Phase 2 | 20 | Pakistan |
| NCT04437823 | Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients | Recruiting | Intravenous Infusions of Stem Cells | Jinnah Hospital|Johns Hopkins University | Phase 2 | 20 | Pakistan |
| NCT04615429 | Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19 | Recruiting | Mesenchymal stromal cells|Other: Placebo | Cristina Avendaño Solá|Puerta de Hierro University Hospital | Phase 2 | 20 | Spain |
| NCT04299152 | Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19 | Not yet recruiting | Stem Cell Educator-Treated Mononuclear Cells Apheresis | Tianhe Stem Cell Biotechnologies Inc. | Phase 2 | 20 | USA |
| NCT04352803 | Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease | Not yet recruiting | Autologous Adipose MSC's | Regeneris Medical | Phase 1 | 20 | USA |
| NCT04384445 | Organicell Flow for Patients With COVID-19 | Not yet recruiting | Organicell Flow|Placebo | Organicell Regenerative Medicine | Phase 1|Phase 2 | 20 | USA |
| NCT04401410 | Anti-SARS Cov-2 T Cell Infusions for COVID 19 | Not yet recruiting | Partially HLA-matched Virus Specific T cells (VSTs) | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System|AlloVir | Phase 1 | 20 | USA |
| NCT04713878 | Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia | Completed | Other: Mesenchymal stem cells | Kanuni Sultan Suleyman Training and Research Hospital | Not Applicable | 21 | Turkey |
| NCT04490486 | Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19 | Not yet recruiting | UCMSCs|Placebo | Joshua M Hare|University of Miami | Phase 1 | 21 | USA |
| NCT04445220 | A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy | Not yet recruiting | SBI-101 | Sentien Biotechnologies, Inc. | Phase 1|Phase 2 | 22 | USA |
| NCT04765449 | Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection | Not yet recruiting | Drug: Cytotoxic T Lymphocytes | Thomas Jefferson University|Tevogen Bio Inc | Phase 1 | 24 | USA |
| NCT04537351 | The MEseNchymal coviD-19 Trial: a Pilot Study to Investigate Early Efficacy of MSCs in Adults With COVID-19 | Recruiting | CYP-001 | Cynata Therapeutics Limited|Cerebral Palsy Alliance Research Institute | Phase 1|Phase 2 | 24 | Australia |
| NCT04634370 | Fase I Clinical Trial on NK Cells for COVID-19 | Not yet recruiting | Natural Killer Cells infusion | Hospital de Clinicas de Porto Alegre | Phase 1 | 24 | Brazil |
| NCT04302519 | Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells | Not yet recruiting | Dental pulp mesenchymal stem cells | CAR-T (Shanghai) Biotechnology Co., Ltd. | Early Phase 1 | 24 | China |
| NCT04590053 | Allocetra-OTS in COVID-19, Phase II | Recruiting | Allocetra-OTS | Hadassah Medical Organization|Barzilai Medical Center|Tel-Aviv Sourasky Medical Center | Phase 2 | 24 | Israel |
| NCT04361942 | Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV) | Recruiting | Mesenchymal Stromal Cells|Placebo | Red de Terapia Celular|Citospin|University of Valladolid|Castilla-León Health Service|Hospital del Río Hortega|Instituto de Salud Carlos III | Phase 2 | 24 | Spain |
| NCT04355728 | Use of UC-MSCs for COVID-19 Patients | Active, not recruiting | Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care|Vehicle + Heparin along with best supportive care | Camillo Ricordi|University of Miami | Phase 1|Phase 2 | 24 | USA |
| NCT04366323 | Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19 | Recruiting | Allogeneic and Expanded Adipose Tissue-Derived Mesenchymal Stem Cells | Andalusian Network for Design and Translation of Advanced Therapies | Phase 1|Phase 2 | 26 | Spain |
| NCT04747574 | Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection | Recruiting | Drug: EXO-CD24 | Tel-Aviv Sourasky Medical Center | Phase 1 | 30 | Israel |
| NCT04760184 | Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden | Not yet recruiting | Other: Autologous stem cell transplantation | Uppsala University|Karolinska University Hospital|Sahlgrenska University Hospital, Sweden|Lund University Hospital|University Hospital, Linkoeping|University Hospital, Umeå|Region Örebro County|Uppsala University Hospital | Observational | 30 | Sweden |
| NCT04276987 | A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia | Not yet recruiting | MSCs-derived exosomes | Ruijin Hospital|Shanghai Public Health Clinical Center|Wuhan Jinyintan Hospital, Wuhan, China|Cellular Biomedicine Group Ltd. | Phase 1 | 30 | China |
| NCT04280224 | NK Cells Treatment for COVID-19 | Recruiting | NK Cells | Xinxiang medical university|First Affiliated Hospital of Xinjiang Medical University | Phase 1 | 30 | China |
| NCT04339660 | Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia | Recruiting | UC-MSCs|Placebo | Puren Hospital Affiliated to Wuhan University of Science and Technology|Shanghai University|Qingdao Co-orient Watson Biotechnology group co. LTD|Basic Medical Sciences, Chinese Academy of Medical Sciences | Phase 1|Phase 2 | 30 | China |
| NCT04429763 | Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia | Not yet recruiting | Umbilical cord derived mesenchymal stem cells|Placebo | Trustem|Fundación Universitaria de Ciencias de la Salud|Hospital de San Jose|Hospital Infantil Universitario de San Jose | Phase 2 | 30 | Colombia |
| NCT04625738 | Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome | Not yet recruiting | Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells|Biological: Placebo | Central Hospital, Nancy, France | Phase 2 | 30 | France |
| NCT04390139 | Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19 | Recruiting | Drug: XCEL-UMC-BETA|Other: Placebo | Banc de Sang i Teixits | Phase 1|Phase 2 | 30 | Spain |
| NCT04392778 | Clinical Use of Stem Cells for the Treatment of Covid-19 | Recruiting | MSC Treatment|Saline Control | SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi|Istinye University|Regenerative Medicine and Stem Cell Production Center Liv MedCell|Liv Hospital (Ulus) | Phase 1|Phase 2 | 30 | Turkey |
| NCT04461925 | Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs | Recruiting | Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells|Antibiotics|Hormones|Anticoagulant Therapy|Oxygen therapy | Institute of Cell Therapy|Kyiv City Clinical Hospital # 4 | Phase 1|Phase 2 | 30 | Ukraine |
| NCT04345601 | Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) | Not yet recruiting | Mesenchymal Stromal Cells|Supportive Care | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System | Early Phase 1 | 30 | USA |
| NCT04399889 | hCT-MSCs for COVID19 ARDS | Recruiting | human cord tissue mesenchymal stromal cells | Joanne Kurtzberg, MD|The Marcus Foundation|Duke University | Phase 1|Phase 2 | 30 | USA |
| NCT04466098 | Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19) | Recruiting | Mesenchymal stromal cells|Placebo | Masonic Cancer Center, University of Minnesota | Phase 2 | 30 | USA |
| NCT04716998 | Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19 | Recruiting | Biological: MesenCure | BonusBio Group Ltd | Phase 1|Phase 2 | 35 | Israel |
| NCT04780685 | A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19 | Recruiting | Biological: hMSC | Stemedica Cell Technologies, Inc.|bioRASI, LLC | Phase 2 | 40 | USA |
| NCT04382547 | Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells | Enrolling by invitation | Allogenic pooled olfactory mucosa-derived mesenchymal stem cells|Standard treatment according to the Clinical protocols | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University | Phase 1|Phase 2 | 40 | Belarus |
| NCT04390152 | Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19 | Not yet recruiting | Wharton's jelly derived Mesenchymal stem cells.|Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) | BioXcellerator|Clinical Somer | Phase 1|Phase 2 | 40 | Colombia |
| NCT04333368 | Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS | Recruiting | Umbilical cord Wharton's jelly-derived human|NaCl 0.9% | Assistance Publique - Hôpitaux de Paris | Phase 1|Phase 2 | 40 | France |
| NCT04377334 | Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS) | Not yet recruiting | MSC | University Hospital Tuebingen | Phase 2 | 40 | Germany |
| NCT04614025 | Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19 | Recruiting | PLX-PAD | Pluristem Ltd. | Phase 2 | 40 | Germany |
| NCT04457609 | Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients | Recruiting | Oseltamivir|Drug: Azithromycin|Biological: Umbilical Cord Mesenchymal Stem Cells | Indonesia University | Phase 1 | 40 | Indonesia |
| NCT04573270 | Mesenchymal Stem Cells for the Treatment of COVID-19 | Completed | PrimePro|Placebo | Thomas Advanced Medical LLC|HeartStem Institute | Phase 1 | 40 | USA |
| NCT04397796 | Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation | Recruiting | BM-Allo.MSC|Placebo | NantKwest, Inc. | Phase 1 | 45 | USA |
| NCT04753476 | Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia | Recruiting | Biological: Injection of Secretome-MSCs|Drug: Standard treatment of Covid-19 | Stem Cell and Cancer Research Indonesia|Provincial Government of Central Java, Indonesia | Phase 2 | 48 | Indonesia |
| NCT04273646 | Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19 | Not yet recruiting | UC-MSCs|Placebo | Wuhan Union Hospital, China|Wuhan Hamilton Bio-technology Co., Ltd, China. | Not Applicable | 48 | China |
| NCT04659304 | Study Evaluating Safety, Tolerability and Efficacy of Allocetra-OTS in Patients With COVID-19 | Not yet recruiting | Allocetra-OTS|Other: Ringer's lactate | Enlivex Therapeutics Ltd. | Phase 1 | 50 | Israel |
| NCT04797975 | Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19 | Not yet recruiting | Biological: KDS-1000|Other: Placebo | Kiadis Pharma | Phase 1|Phase 2 | 54 | Netherlands |
| NCT04798716 | The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 | Not yet recruiting | Drug: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)|Drug: MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)|Drug: MSC-exosomes delivered intravenously every other day (8:8:8) | AVEM HealthCare | Phase 1|Phase 2 | 55 | USA |
| NCT04349631 | A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 | Enrolling by invitation | HB-adMSCs | Hope Biosciences | Phase 2 | 56 | USA |
| NCT04578210 | Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia | Recruiting | T memory cells and NK cells | Instituto de Investigación Hospital Universitario La Paz|Universidad Autonoma de Madrid|Universidad Miguel Hernandez de Elche|Asociación Instituto de Investigación Sanitaria BioCruces|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana | Phase 1|Phase 2 | 58 | Spain |
| NCT04371601 | Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 | Active, not recruiting | Drug: Oseltamivir|Drug: hormones|Device: oxygen therapy|Procedure: mesenchymal stem cells | Fuzhou General Hospital | Early Phase 1 | 60 | China |
| NCT04639440 | Impact of Adipose Tissue in COVID-19 | Not yet recruiting | Other: Adipose tissue | Assistance Publique - Hôpitaux de Paris | 60 | France | |
| NCT04366063 | Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome | Recruiting | Cell therapy protocol 1|Cell therapy protocol 2 | Royan Institute|Tehran University of Medical Sciences|Shahid Beheshti University of Medical Sciences | Phase 2|Phase 3 | 60 | Iran |
| NCT04389385 | COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo) | Active, not recruiting | COVID-19 Specific T Cell derived exosomes (CSTC-Exo) | TC Erciyes University | Phase 1 | 60 | Turkey |
| NCT04494386 | Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS | Recruiting | Umbilical Cord Lining Stem Cells (ULSC)|Placebo (carrier control) | Restem, LLC. | Phase 1|Phase 2 | 60 | USA |
| NCT04623671 | Intravenous Infusion of CAP-1002 in Patients With COVID-19 | Recruiting | CAP-1002|Biological: Placebo | Capricor Inc. | Phase 2 | 60 | USA |
| NCT04398303 | ACT-20 in Patients With Severe COVID-19 Pneumonia | Not yet recruiting | ACT-20-MSC|ACT-20-CM|Placebo | Aspire Health Science | Phase 1|Phase 2 | 70 | USA |
| NCT04565665 | Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome | Recruiting | Best Practice|Mesenchymal Stem Cell | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Phase 1 | 70 | USA |
| NCT04629105 | Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Longeveron Mesenchymal Stem Cells (LMSCs) (RECOVER) | Recruiting | Longeveron Mesenchymal Stem Cells (LMSCs)|Other: Placebo | Longeveron LLC | Phase 1 | 70 | USA |
| NCT03042143 | Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19) | Recruiting | Human Umbilical Cord Derived CD362 Enriched MSCs|Placebo (Plasma-Lyte 148) | Belfast Health and Social Care Trust|Queen's University, Belfast|Northern Ireland Clinical Trials Unit|NHS Blood and Transplant | Phase 1|Phase 2 | 75 | UK |
| NCT04365101 | Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNK-001-COVID-19) | Recruiting | CYNK-001 | Celularity Incorporated|IDRI|Lung Biotechnology PBC|California Institute for Regenerative Medicine (CIRM) | Phase 1|Phase 2 | 86 | USA |
| NCT04482699 | RAPA-501-Allo Off-the-Shelf Therapy of COVID-19 | Not yet recruiting | RAPA-501-Allo off-the-shelf Therapy of COVID-19|Placebo | Rapa Therapeutics LLC|Hackensack Meridian Health | Phase 1|Phase 2 | 88 | USA |
| NCT04315987 | NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia | Not yet recruiting | NestaCell®|Placebo | Azidus Brasil|Cellavita Pesquisa Científica Ltda|Hospital Vera Cruz | Phase 2 | 90 | Brazil |
| NCT04324996 | A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19 | Recruiting | NK cells, IL15-NK cells, NKG2D CAR-NK cells, ACE2 CAR-NK cells, NKG2D-ACE2 CAR-NK cells | Chongqing Public Health Medical Center|Chongqing Sidemu Biotechnology Technology Co.,Ltd. | Phase 1|Phase 2 | 90 | China |
| NCT04602442 | Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia | Enrolling by invitation | EXO 1 inhalation|Drug: EXO 2 inhalation|Drug: Placebo inhalation | Olga Tyumina|Clinics of the Federal State Budgetary Educational Institution SSMU|Samara Regional Clinical Hospital V.D. Seredavin|State-Financed Health Facility "Samara Regional Medical Center Dinasty" | Phase 2 | 90 | Russia |
| NCT04728698 | Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress | Not yet recruiting | Drug: COVI-MSC|Drug: Placebo | Sorrento Therapeutics, Inc. | Phase 2 | 100 | USA |
| NCT04288102 | Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19) | Active, not recruiting | UC-MSCs|Saline containing 1% Human serum albumin (solution without UC-MSCs) | Beijing 302 Hospital|Huoshenshan Hospital|Maternal and Child Health Hospital of Hubei Province|General Hospital of Central Theater Command, Wuhan, China|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China | Phase 2 | 100 | China |
| NCT04393415 | Using PRP and Cord Blood in Treatment of Covid -19 | Recruiting | Stem cells | Aljazeera Hospital | Not Applicable | 100 | Egypt |
| NCT04348461 | BAttLe Against COVID-19 Using MesenchYmal Stromal Cells | Not yet recruiting | Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Instituto de Investigación Sanitaria y Biomédica de Alicante|Hospital General Universitario Gregorio Marañon|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Universitario de Salamanca|Hospital General Universitario de Alicante|Hospital Clínico Universitario Virgen de la Arrixaca | Phase 2 | 100 | Spain |
| NCT04348435 | A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 | Enrolling by invitation | HB-adMSCs|Placebos | Hope Biosciences|Hope Biosciences Stem Cell Research Foundation | Phase 2 | 100 | USA |
| NCT04406064 | Viral Specific T-cells for Treatment of COVID-19 | Not yet recruiting | Viral Specific T-cells (VSTs) | Children's Hospital Medical Center, Cincinnati|Hoxworth Blood Center | Phase 2 | 100 | USA |
| NCT04362189 | Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 | Active, not recruiting | HB-adMSC|Placebo | Hope Biosciences|Advanced Diagnostics Healthcare|Hope Biosciences Stem Cell Research Foundation|United Memorial Medical Center | Phase 2 | 100 | USA |
| NCT04366271 | Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19 | Recruiting | Mesenchymal cells|Standard of care | Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Apices Soluciones S.L. | Phase 2 | 106 | Spain |
| NCT04724642 | COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency | Recruiting | Tel-Aviv Sourasky Medical Center | Observational | 110 | Israel | |
| NCT04590261 | Myeloid Cells in Patients With Covid-19 Pneumonia | Not yet recruiting | Blood sampling|Nasal Brushing | Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France | Not Applicable | 120 | France |
| NCT04389450 | Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 | Recruiting | PLX-PAD|Placebo | Pluristem Ltd. | Phase 2 | 140 | USA |
| NCT04473170 | Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19 | Completed | Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|COVID-19 standard care | Abu Dhabi Stem Cells Center | Phase 1|Phase 2 | 146 | UAE |
| NCT04428801 | Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 | Not yet recruiting | Autologous adipose-derived stem cells | Celltex Therapeutics Corporation | Phase 2 | 200 | USA |
| NCT04371393 | MSCs in COVID-19 ARDS | Recruiting | Remestemcel-L|Placebo | Icahn School of Medicine at Mount Sinai|Mesoblast, Inc. | Phase 3 | 300 | USA |
| NCT04367077 | MultiStem Administration for COVID-19 Induced ARDS (MACoVIA) | Recruiting | MultiStem|Placebo | Athersys, Inc | Phase 2|Phase 3 | 400 | USA |
| NCT04657406 | Expanded Access to ZofinTM (OrganicellTM Flow) for Patients With COVID-19 | Available | ZofinTM (OrganicellTM Flow) | Organicell Regenerative Medicine|bioRASI, LLC | Expanded Access | ||
| NCT04657458 | Expanded Access Protocol on Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Infusion Treatment for Patients With COVID-19 Associated ARDS | Available | Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment | Direct Biologics, LLC | Expanded Access | ||
| NCT04338347 | CAP-1002 in Severe COVID-19 Disease | Available | CAP-1002 Allogeneic Cardiosphere-Derived Cells | Capricor Inc. | USA | ||
| NCT04366830 | Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection | No longer available | Remestemcel-L | Mesoblast International Sàrl|Mesoblast, Ltd. | USA | ||
| NCT04456439 | Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19) | Available | Remestemcel-L|Drug: Hydrocortisone|Drug: Diphenhydramine | Mesoblast International SÃ rl|Mesoblast, Ltd. | USA |